M. Azodi

发表

MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer

R. Chen, G. Mor, D. Silasi, 2006, The Yale journal of biology and medicine.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression

E. Ratner, Serena Wong, D. Silasi, 2016, Molecular Cancer Therapeutics.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

B. Monk, D. Matei, A. Oza, 2019, The Lancet. Oncology.

In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.

Gloria S. Huang, E. Ratner, D. Silasi, 2019, Gynecologic oncology.

Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo

Gloria S. Huang, E. Ratner, D. Silasi, 2019, Molecular oncology.

Bevacizumab Related Hypertension and Reversible Posterior Leukoencephalopathy Syndrome in Gynecologic Malignancies: A Case Control Study

E. Ratner, D. Silasi, P. Schwartz, 2011 .

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas

Gloria S. Huang, E. Ratner, R. Angioli, 2020, Oncotarget.

Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.

E. Ratner, D. Silasi, P. Schwartz, 2011, American journal of obstetrics and gynecology.

Glyceraldehyde-3-phosphate dehydrogenase binds to the AU-Rich 3' untranslated region of colony-stimulating factor-1 (CSF-1) messenger RNA in human ovarian cancer cells: possible role in CSF-1 posttranscriptional regulation and tumor phenotype.

M. Azodi, Yi Zhou, S. Chambers, 2005, Cancer research.

SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.

Gloria S. Huang, E. Ratner, Serena Wong, 2017, Gynecologic oncology.

Evaluation of the Ctytotoxic Effect of Cuminum cyminum essential oils on Human Colon Cancer cell line SW742

M. Azodi, S. F. far, saeyd heydari kashel, 2013 .

A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.

Gloria S. Huang, Abhijit A. Patel, D. Levine, 2018, Gynecologic oncology.

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

Gloria S. Huang, E. Ratner, D. Silasi, 2020, Scientific Reports.

Expression of Tissue factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix: Implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor

D. Silasi, P. Schwartz, T. Rutherford, 2011, BMC Cancer.

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

E. Ratner, D. Silasi, P. Schwartz, 2013, Clinical & Experimental Metastasis.

Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.

L. Alexandrov, E. Ratner, M. Azodi, 2022, Gynecologic oncology.

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).

L. Alexandrov, A. Iwasaki, E. Ratner, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

HER-2/NEU overexpression in vulvar Paget disease: the Yale experience

D. Silasi, P. Schwartz, T. Rutherford, 2010, Journal of Clinical Pathology.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression

E. Ratner, Serena Wong, D. Silasi, 2017, Clinical Cancer Research.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

T-DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo

E. Ratner, D. Silasi, P. Schwartz, 2014, Cancer medicine.

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab

E. Ratner, D. Silasi, T. Rutherford, 2011, British Journal of Cancer.

Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor

D. Silasi, P. Schwartz, T. Rutherford, 2011, Clinical & Experimental Metastasis.

Phase I Clinical Trial of the Mammalian Target of Rapamycin Inhibitor Everolimus in Combination With Oral Topotecan for Recurrent and Advanced Endometrial Cancer

E. Ratner, D. Silasi, P. Schwartz, 2014, International Journal of Gynecologic Cancer.

Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.

J. McAlpine, Herbert Yu, M. Kelly, 2005, Gynecologic oncology.

Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer

E. Ratner, P. Schwartz, M. Azodi, 2015, International Journal of Gynecologic Cancer.

Port-Site Metastasis in Gynecological Malignancies

M. Azodi, P. Hui, G. Menderes, 2021, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

Isolated port site recurrence of node-negative clinical stage IB1 cervical adenocarcinoma

M. Azodi, P. Hui, Molly McAdow, 2017, Gynecologic oncology reports.

The significance of perineural invasion in early-stage cervical cancer.

E. Ratner, D. Silasi, J. Illuzzi, 2011, Gynecologic oncology.

Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation.

J. McAlpine, J. Dziura, M. Kelly, 2004, Gynecologic oncology.

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo

E. Ratner, D. Silasi, T. Rutherford, 2014, British Journal of Cancer.

Financial toxicity in patients with gynecologic malignancies: a cross sectional study

Gloria S. Huang, E. Ratner, P. Schwartz, 2021, Journal of gynecologic oncology.

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.

L. Alexandrov, E. Ratner, M. Azodi, 2022, Gynecologic oncology.

Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Inhibition of the c-fms proto-oncogene autocrine loop and tumor phenotype in glucocorticoid stimulated human breast carcinoma cells

M. Azodi, S. Chambers, E. Toy, 2011, Breast Cancer Research and Treatment.

Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.

E. Ratner, M. Azodi, P. Hui, 2022, Gynecologic oncology.

QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.

B. Monk, A. Oza, J. Berek, 2018 .

High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of contemporary brachytherapy.

Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.

J. McAlpine, Herbert Yu, M. Kelly, 2005, Gynecologic oncology.

Atypical presentations of carboplatin hypersensitivity reactions: characterization and management in patients with gynecologic malignancies.

J. McAlpine, M. Kelly, P. Schwartz, 2006, Gynecologic oncology.

Urinary hCG Screening in the Gynecologic Oncology Population

D. Silasi, P. Schwartz, T. Rutherford, 2011 .

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition

S. Mane, T. Boggon, Kaya Bilgüvar, 2016, Proceedings of the National Academy of Sciences.

PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.

Gloria S. Huang, G. Frampton, J. Newberg, 2019, Gynecologic oncology.

Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

E. Ratner, R. Angioli, D. Silasi, 2015, Molecular Cancer Therapeutics.

Dual HER 2 / PIK 3 CA Targeting Overcomes Single-Agent Acquired Resistance in HER 2-Ampli fi ed Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo

E. Ratner, R. Angioli, D. Silasi, 2015 .

Integrated mutational landscape analysis of uterine leiomyosarcomas

Gloria S. Huang, M. Imieliński, L. Alexandrov, 2021, Proceedings of the National Academy of Sciences.

Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.

L. Alexandrov, P. Dottino, E. Ratner, 2022, Gynecologic oncology.

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors

Gloria S. Huang, R. Lifton, J. Schlessinger, 2018, Proceedings of the National Academy of Sciences.

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo

Pei Hui, Jonathan Black, David L Rimm, 2016, British Journal of Cancer.

Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines

F. Casagrande, D. Silasi, P. Schwartz, 2009, Journal of Virology.

Induction of human tumor‐associated differentially expressed gene‐12 (TADG‐12/TMPRSS3)‐specific cytotoxic T lymphocytes in human lymphocyte antigen‐A2.1–positive healthy donors and patients with advanced ovarian cancer

T. O'brien, S. Anfossi, D. Silasi, 2009, Cancer.

Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.

T. O'brien, S. Anfossi, D. Silasi, 2009, American journal of obstetrics and gynecology.

Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects

A. Oza, J. Berek, G. Lindahl, 2022, Cancer research communications.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

Mads Thomassen, Nina Ditsch, Muhammad Usman Rashid, 2015, JAMA.

Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer

Gloria S. Huang, E. Ratner, D. Silasi, 2018, Journal of Cancer Research and Clinical Oncology.

Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study.

E. Ratner, D. Silasi, P. Schwartz, 2017, Gynecologic oncology.

Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV)

Herbert Yu, D. Silasi, P. Schwartz, 2013, Journal of surgical oncology.

Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease.

J. McAlpine, Herbert Yu, M. Kelly, 2007, Gynecologic oncology.

Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

A. Secord, E. Ratner, L. Havrilesky, 2020, Clinical Cancer Research.

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

A. Secord, E. Ratner, L. Havrilesky, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma

F. Casagrande, D. Silasi, T. Rutherford, 2009, British Journal of Cancer.

Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.

J. McAlpine, M. Kelly, P. Schwartz, 2005, Gynecologic oncology.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy

E. Ratner, D. Silasi, T. Rutherford, 2012, British Journal of Cancer.

Eradication of chemotherapy‐resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin

F. Casagrande, P. Schwartz, T. Rutherford, 2011, Cancer.

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

Gloria S. Huang, L. Alexandrov, A. Iwasaki, 2021, Cancer.

Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma

T. Boggon, Murim Choi, Shrikant Mane, 2013, Proceedings of the National Academy of Sciences.

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Christiana Kartsonaki, Mads Thomassen, Etienne Rouleau, 2011, Human molecular genetics.

Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment

G. Mor, D. Silasi, A. Alvero, 2013, Cancer Medicine.

Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment

G. Mor, D. Silasi, A. Alvero, 2013, Cancer medicine.

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

E. Ratner, D. Silasi, P. Schwartz, 2013, Clinical & Experimental Metastasis.

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel

E. Ratner, D. Silasi, P. Schwartz, 2013, Clinical & Experimental Metastasis.

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Tumor Biology.

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

Gautam G. Rao, E. Ratner, D. Silasi, 2022, British Journal of Cancer.

Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.

Gloria S. Huang, E. Ratner, P. Schwartz, 2021, Gynecologic oncology.

Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

Gloria S. Huang, L. Alexandrov, T. Boggon, 2019, Proceedings of the National Academy of Sciences.

High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.

D. Silasi, P. Schwartz, T. Rutherford, 2010, American journal of obstetrics and gynecology.

Overexpression of Epithelial Cell Adhesion Molecule in Primary, Metastatic, and Recurrent/Chemotherapy-Resistant Epithelial Ovarian Cancer: Implications for Epithelial Cell Adhesion Molecule-Specific Immunotherapy

D. Silasi, P. Schwartz, T. Rutherford, 2009, International Journal of Gynecologic Cancer.

Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor.

C. Zeiss, M. Azodi, S. Chambers, 2009, Neoplasia.

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

E. Ratner, D. Silasi, T. Rutherford, 2015, Cancer.

Primary Cervical Carcinoma Cell Lines Overexpress Epithelial Cell Adhesion Molecule (EpCAM) and Are Highly Sensitive to Immunotherapy With MT201, a Fully Human Monoclonal Anti-EpCAM Antibody

F. Casagrande, D. Silasi, P. Schwartz, 2010, International Journal of Gynecologic Cancer.

Peritoneal tuberculosis with elevated serum Ca-125 level mimicking advanced stage ovarian cancer: a case report

M. Azodi, T. Pua, O. Tan, 2009, Archives of Gynecology and Obstetrics.

Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

E. Ratner, D. Silasi, P. Schwartz, 2020, Frontiers in Oncology.

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

Gloria S. Huang, E. Ratner, D. Silasi, 2020, Scientific Reports.

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.

E. Ratner, M. Azodi, P. Hui, 2022, Gynecologic oncology.

DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.

Gloria S. Huang, E. Ratner, D. Silasi, 2021, Gynecologic oncology.

The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.

P. Dottino, E. Ratner, M. Azodi, 2023, Gynecologic oncology.

Overexpression of EpCAM in Uterine Serous Papillary Carcinoma: Implications for EpCAM-Specific Immunotherapy With Human Monoclonal Antibody Adecatumumab (MT201)

F. Casagrande, D. Silasi, P. Schwartz, 2010, Molecular Cancer Therapeutics.

Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

Gloria S. Huang, E. Ratner, E. Siegel, 2021, Gynecologic Oncology.

Institutional Review of Primary Non-Hodgkin Lymphoma of the Female Genital Tract: A 33-Year Experience

E. Ratner, P. Schwartz, T. Rutherford, 2014, International Journal of Gynecologic Cancer.

hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma

G. Krikun, F. Casagrande, D. Silasi, 2010, British Journal of Cancer.

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors

L. Harris, D. Zelterman, S. Gettinger, 2015, Cancer.

Chlamydia Peritonitis and Ascites Mimicking Ovarian Cancer

M. Azodi, A. Gojayev, D. English, 2016, Case reports in obstetrics and gynecology.

Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer

E. Ratner, F. Casagrande, D. Silasi, 2009, British Journal of Cancer.

Large Prospective Study of Ovarian Cancer Screening in High-Risk Women: CA125 Cut-Point Defined by Menopausal Status

A. Berchuck, M. Greene, S. Buys, 2011, Cancer Prevention Research.

Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.

J. Schlessinger, E. Ratner, G. Bollag, 2023, Gynecologic oncology.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

An unexpected mass of the urachus: a case report.

M. Azodi, J. Black, N. Buza, 2014, American journal of obstetrics and gynecology.

Management of Borderline Ovarian Tumors Based on Patient and Tumor Characteristics

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic and Obstetric Investigation.

Ovarian preservation and staging in reproductive-age endometrial cancer patients.

B. Qian, Herbert Yu, P. Schwartz, 2009, Gynecologic oncology.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

N. Rothman, Q. Lan, E. Ratner, 2015, British Journal of Cancer.

Brain Metastases in Epithelial Ovarian and Primary Peritoneal Carcinoma

J. McAlpine, E. Ratner, P. Schwartz, 2009, International Journal of Gynecologic Cancer.

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

E. Ratner, D. Silasi, M. Azodi, 2019, Scientific Reports.

Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.

E. Sartori, E. Ratner, D. Silasi, 2017, Gynecologic oncology.

Phase II Evaluation of Phenoxodiol in Combination With Cisplatin or Paclitaxel in Women With Platinum/Taxane-Refractory/Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

A. Husband, G. Mor, M. Kelly, 2011, International Journal of Gynecologic Cancer.

Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.

Gloria S. Huang, E. Ratner, Serena Wong, 2017, Gynecologic oncology.

PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.

Gloria S. Huang, E. Ratner, D. Silasi, 2019, Gynecologic oncology.

Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer

Gloria S. Huang, J. Schlessinger, E. Ratner, 2018, Clinical Cancer Research.

In Vitro and In Vivo Activity of IMGN853, an Antibody–Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers

Gloria S. Huang, E. Ratner, Serena Wong, 2018, Molecular Cancer Therapeutics.

Flutamide and Biomarkers in Women at High Risk for Ovarian Cancer: Preclinical and Clinical Evidence

M. Azodi, Yi Zhou, Wenxin Zheng, 2014, Cancer Prevention Research.

Flutamide andBiomarkers inWomen at HighRisk for Ovarian Cancer: Preclinical and Clinical Evidence

M. Azodi, Yi Zhou, Wenxin Zheng, 2014 .

Title: Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence

M. Azodi, Yi Zhou, Wenxin Zheng, 2014 .

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells

E. Ratner, W. Saltzman, D. Silasi, 2016, Molecular Cancer Therapeutics.

Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody

Paola Todeschini, Masoud Azodi, Marta Betti, 2011, Journal of experimental & clinical cancer research : CR.

Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo

E. Ratner, D. Silasi, P. Schwartz, 2017, Medical Oncology.

Baseline platelet count and body weight as predictors of early dose modification in the quadra trial of niraparib monotherapy for the treatment of heavily pretreated (≥4th line), advanced, recurrent high-grade serous ovarian cancer

B. Monk, A. Oza, J. Berek, 2019, Gynecologic Oncology.

Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones

E. Ratner, D. Silasi, T. Rutherford, 2013, Cancer.

Clostridium perfringens enterotoxin C‐terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy‐resistant ovarian cancer

C. Zeiss, E. Ratner, W. Saltzman, 2015, International journal of cancer.

Adjuvant Carboplatin, Paclitaxel, and Vaginal Cuff Brachytherapy for Stage III Endometrial Cancer: Analysis of Outcomes and Patterns of Recurrence Based on Pathologic Characteristics

E. Ratner, D. Silasi, P. Schwartz, 2014, International Journal of Gynecologic Cancer.

Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer

E. Ratner, D. Silasi, P. Schwartz, 2018, Gynecologic oncology reports.

Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer.

Masoud Azodi, E. Ratner, D. Silasi, 2012, Gynecologic oncology.

Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma

E. Ratner, D. Silasi, P. Schwartz, 2018, Reproductive Sciences.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.

E. Ratner, D. Silasi, P. Schwartz, 2016, American journal of obstetrics and gynecology.

Ovarian Preservation and Staging in Reproductive-Age Endometrial Cancer Patients

B. Qian, Herbert Yu, P. Schwartz, 2009 .

A survey of gynecologic oncologists regarding the end-of-life discussion: a pilot study.

E. Ratner, D. Silasi, J. Illuzzi, 2012, Gynecologic oncology.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of experimental & clinical cancer research : CR.

Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma.

Gloria S. Huang, E. Ratner, D. Silasi, 2020, Gynecologic oncology.

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

P. Dottino, E. Ratner, M. Azodi, 2023, Annals of Surgical Oncology.

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

E. Ratner, D. Silasi, P. Schwartz, 2015, British Journal of Cancer.

Extrarenal Wilms' tumor of the uterine corpus.

J. McAlpine, M. Kelly, T. Rutherford, 2005, Gynecologic oncology.

Risk‐stratifying clinicopathologic criteria for ovarian preservation in premenopausal women with early stage low‐risk endometrial cancer

E. Ratner, M. Azodi, G. Menderes, 2020, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Abstract NT-101: QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENS

B. Monk, A. Oza, J. Berek, 2019 .

Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy

E. Siegel, E. Ratner, D. Silasi, 2013, British Journal of Cancer.

Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.

E. Ratner, D. Silasi, P. Schwartz, 2015, Gynecologic oncology.

Weekly ixabepilone with or without concurrent bevacizumab in the treatment of recurrent endometrial cancer.

E. Ratner, D. Silasi, P. Schwartz, 2012 .

Carcinosarcoma of the ovary

G. Mor, D. Silasi, J. Illuzzi, 2007, International Journal of Gynecologic Cancer.

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

V. Pankratz, F. Couch, T. Rebbeck, 2011, Human molecular genetics.

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Journal of experimental & clinical cancer research : CR.

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

E. Ratner, D. Silasi, T. Rutherford, 2015, Cancer.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

A. Whittemore, F. Couch, B. Bonanni, 2015 .

A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.

Gloria S. Huang, Abhijit A. Patel, D. Levine, 2018, Gynecologic oncology.

Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.

E. Ratner, M. Azodi, B. Paolini, 2024, Proceedings of the National Academy of Sciences of the United States of America.

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro

E. Ratner, D. Silasi, P. Schwartz, 2015, Tumor Biology.